Article
The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA.
Blood - 4 Feb 2010
Burnett Alan K, Hills Robert K, Green Claire, Jenkinson Sarah, Koo Kenneth, Patel Yashma, Guy Carol, Gilkes Amanda, Milligan Donald W, Goldstone Anthony H, Prentice Archibald G, Wheatley Keith, Linch David C, Gale Rosemary E
Abstract excerpt
We investigated the benefit of adding all-trans retinoic acid (ATRA) to chemotherapy for younger patients with nonacute promyelocytic acute myeloid leukemia and high-risk myelodysplastic syndrome, and considered interactions between treatment and molecular markers. Overall, 1075 patients less tha...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.